| Date Filed | Type | Description |
| 08/24/2023 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 18,600 shares
@ $20.01, valued at
$372.2k
Exercised 13,600 options to buy
@ $3.3, valued at
$44.9k
Exercised 5,000 options to buy
@ $15.5, valued at
$77.5k
|
|
| 08/15/2023 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 1,400 shares
@ $20, valued at
$28k
Exercised 1,400 options to buy
@ $3.3, valued at
$4.6k
|
|
| 08/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 08/03/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 07/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/15/2023 |
4
| Lewis Tanya (Chief Dev. Op. Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 12,043 shares
@ $24.1, valued at
$290.2k
Sold 817 shares
@ $23.45, valued at
$19.2k
|
|
| 06/15/2023 |
4
| Patel Sushil (Chief Strategy Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 5,145 shares
@ $24.11, valued at
$124k
Sold 553 shares
@ $23.44, valued at
$13k
|
|
| 05/18/2023 |
3
| Schwendenman Andrew (Chief Accounting Officer) has filed a Form 3 on Replimune Group, Inc. |
| 05/18/2023 |
4
| Patel Sushil (Chief Strategy Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 15,575 shares
@ $18.05, valued at
$281.1k
|
|
| 05/18/2023 |
4
| Coffin Robert (President & Chief R&D Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 7,861 shares
@ $18.05, valued at
$141.9k
|
|
| 05/18/2023 |
4
| Lewis Tanya (Chief Dev. Op. Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 12,207 shares
@ $18.05, valued at
$220.3k
|
|
| 05/18/2023 |
4
| Love Colin (COO) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 10,775 shares
@ $18.05, valued at
$194.5k
|
|
| 05/18/2023 |
4
| Franchi Jean M. (CFO) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 11,351 shares
@ $18.05, valued at
$204.9k
|
|
| 05/18/2023 |
4
| Xynos Konstantinos (Chief Medical Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 771 shares
@ $18.05, valued at
$13.9k
|
|
| 05/18/2023 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 5,966 shares
@ $18.05, valued at
$107.7k
|
|
| 05/18/2023 |
4
| Astley-Sparke Philip (CEO) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Sold 17,902 shares
@ $18.05, valued at
$323.1k
|
|
| 05/18/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/18/2023 |
10-K
| Annual Report for the period ended March 31, 2023 |
| 05/18/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
4
| Slootweg Hugo Alexander (Director) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
| 04/04/2023 |
4
| Pucci Paolo (Director) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
| 04/04/2023 |
4
| Dhingra Kapil (Director) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
| 04/04/2023 |
4
| SLATTERY JOSEPH P (Director) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
| 04/04/2023 |
4
| Levitsky Hyam (Director) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
| 04/04/2023 |
4
| Weinand Dieter (Director) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Granted 37,800 options to buy
@ $17.66, valued at
$667.5k
|
|
| 04/04/2023 |
4
| Oliger Christy J. (Director) has filed a Form 4 on Replimune Group, Inc.|
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
|